These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 1319823

  • 1. Antitumor activity of magainin analogues against human lung cancer cell lines.
    Ohsaki Y, Gazdar AF, Chen HC, Johnson BE.
    Cancer Res; 1992 Jul 01; 52(13):3534-8. PubMed ID: 1319823
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines.
    Lehmann J, Retz M, Sidhu SS, Suttmann H, Sell M, Paulsen F, Harder J, Unteregger G, Stöckle M.
    Eur Urol; 2006 Jul 01; 50(1):141-7. PubMed ID: 16476519
    [Abstract] [Full Text] [Related]

  • 3. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
    Ali MA, Rosati R, Pettit GR, Kalemkerian GP.
    Anticancer Res; 1998 Jul 01; 18(2A):1021-6. PubMed ID: 9615758
    [Abstract] [Full Text] [Related]

  • 4. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
    Gilbert JA, Frederick LM, Ames MM.
    Clin Cancer Res; 2000 Nov 01; 6(11):4365-72. PubMed ID: 11106255
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.
    Georgiadis MS, Russell EK, Gazdar AF, Johnson BE.
    Clin Cancer Res; 1997 Mar 01; 3(3):449-54. PubMed ID: 9815704
    [Abstract] [Full Text] [Related]

  • 6. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA.
    Clin Cancer Res; 2002 May 01; 8(5):1280-7. PubMed ID: 12006549
    [Abstract] [Full Text] [Related]

  • 7. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.
    Cancer Res; 1992 Oct 15; 52(20):5674-80. PubMed ID: 1327513
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.
    Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F.
    J Clin Invest; 1988 Jul 15; 82(1):354-9. PubMed ID: 2839551
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
    Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N.
    Anticancer Res; 1996 Jul 15; 16(6B):3387-95. PubMed ID: 9042196
    [Abstract] [Full Text] [Related]

  • 10. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 11. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP, Ou X.
    Cancer Chemother Pharmacol; 1999 Aug 01; 43(2):145-50. PubMed ID: 9923820
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
    Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N.
    Cancer Res; 1995 Mar 01; 55(5):1075-9. PubMed ID: 7866991
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
    Takigawa N, Ohnoshi T, Ueoka H, Horiguchi T, Kiura K, Tabata M, Segawa Y, Shibayama T, Genba K, Matsumura T.
    Gan To Kagaku Ryoho; 1993 Jul 01; 20(9):1221-6. PubMed ID: 8392827
    [Abstract] [Full Text] [Related]

  • 17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK, Davey MW, Davey RA.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):256-65. PubMed ID: 16283310
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
    Kaufmann SH, Kalemkerian GP, Jasti R, Mabry M.
    Biochem Pharmacol; 1995 Dec 22; 50(12):1987-93. PubMed ID: 8849324
    [Abstract] [Full Text] [Related]

  • 20. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
    Kiura K, Ohnoshi T, Ueoka H, Takigawa N, Tabata M, Segawa Y, Shibayama T, Kimura I.
    Anticancer Drug Des; 1992 Dec 22; 7(6):463-70. PubMed ID: 1337430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.